2024
Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia
Mims A, Xie Z, Potluri R, Rotter D, Chevli M, Prebet T, Gaugler L, Strocchia M, Vasconcelos A, Sieluk J. Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia. Leukemia & Lymphoma 2024, ahead-of-print: 1-9. PMID: 39606887, DOI: 10.1080/10428194.2024.2425792.Peer-Reviewed Original ResearchRelapse-free survivalNewly diagnosed acute myeloid leukemiaOral-AZAIntensive chemotherapyAcute myeloid leukemiaOverall survivalMyeloid leukemiaMedian relapse-free survivalFlatiron Health databasePropensity score matched cohortCompare treatment patternsScore-matched cohortAzacitidine maintenanceND-AMLOral azacitidineMedian OSRetrospective studyClinical outcomesTreatment patternsAzacitidineTransplant candidatesPatientsReal-world outcomesRemissionChemotherapyCorrigendum to “AML-068 - Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but Not Treated in a US Electronic Health Record (EHR) Database” [Clinical Lymphoma, Myeloma & Leukemia, 23S1 (2023) S1-S593]
Mims A, Xie Z, Vasconcelos A, Strocchia M, Heydendael W, Chevli M, Rotter D, Potluri R, Prebet T, Sieluk J. Corrigendum to “AML-068 - Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but Not Treated in a US Electronic Health Record (EHR) Database” [Clinical Lymphoma, Myeloma & Leukemia, 23S1 (2023) S1-S593]. Clinical Lymphoma Myeloma & Leukemia 2024, 24: 203-204. DOI: 10.1016/j.clml.2023.11.010.Peer-Reviewed Original Research
2023
EE86 Healthcare Resource Utilization (HCRU) and Associated Costs Among Patients with Acute Myeloid Leukemia (AML) Treated with Oral Azacitidine as Maintenance and Those Eligible but Not Treated Using a US Claims Database
Borate U, Seiter K, Potluri R, Mazumder D, Heydendael W, Chevli M, Prebet T, Strocchia M, Vasconcelos A, Sieluk J. EE86 Healthcare Resource Utilization (HCRU) and Associated Costs Among Patients with Acute Myeloid Leukemia (AML) Treated with Oral Azacitidine as Maintenance and Those Eligible but Not Treated Using a US Claims Database. Value In Health 2023, 26: s67. DOI: 10.1016/j.jval.2023.09.358.Peer-Reviewed Original Research